Rosalind Franklin University Helix 51 Company Saros Therapeutics Receives Second $2 Million Award to Advance Cancer Immunotherapy

Phase 2Positive

AI Analysis

Summary

Saros Therapeutics, a company from Rosalind Franklin University's Helix 51 incubator, received its second $2 million Phase II award from the National Cancer Institute to advance cancer immunotherapy development.

Clinical Trial Data

Phase

Phase II

Outcome Details

Saros Therapeutics received a second $2 million Phase II award from the National Cancer Institute

Importance:5/10

Sentiment:

0.70

cancer_immunotherapyNCI_fundinguniversity_spinoutgrant_award

Related Companies

$NHPAP

Read the original article

Published by PR Newswire Clinical Trials on October 2, 2026 4:00 PM

Read Original